New compound eases neuropathic pain from light touch
An anesthetic injection like that given by a dentist numbs all feeling in the surrounding tissue. This is often the only approach for treating people who suffer from a painful hypersensitivity that often accompanies nerve damage. Anesthetics that shut down all the functions of mechanosensory nerves reduce pain, but they also prevent other important signals from getting through.
Using the EU OPENSCREEN screening platform, which is jointly operated by the MDC and the Leibniz-Institut für Molekulare Pharmakologie (FMP), Cécile-Vogt fellow Dr. Kate Poole, Dr. Christiane Wetzel and their colleagues in the research team of Prof. Gary Lewin at the MDC and Charité – Universitätsmedizin Berlin have now identified a substance that suppresses pain from mechanical stimuli without disturbing other sensations.
Very light touch is detected by a molecular sensor in the skin, an ion channel called "Piezo2". Such channels are like tiny valves in the membranes of neurons which open once they experience stress from movement in the skin. When open, electrically charged particles pass through the valve. This creates an electrical signal which the cell then amplifies and forwards to the spine. The protein STOML3 tunes the mechanical sensitivity of Piezo2 ion channel.
The researchers subjected the STOML3 protein to a drug screen, testing 35,000 different chemicals in large-scale in vitro experiments. They identified a substance called OB-1 which prevents STOML3 from forming clusters and thereby inhibits its function. Further electrochemical measurements of cells confirmed that when this didn't happen, the Piezo2 ion channel remained closed.
Most importantly, the chemical effectively suppressed only this type of mechanical sensation in mice without affecting other types of sensation. Under the influence of OB-1, the animals' sensitivity to light touch was significantly reduced. After the effects of the drug had worn off, the animals' sensitivity returned to normal levels.
"Colleagues at the MDC designed a set of behavioral experiments in which the animals could 'talk' to us," Lewin says. "Small amounts of the substance were administered to the mouse paw. The paw was then gently tapped. The mice had been trained to reach for a reward when they felt it.
The OB-1 drug had a dramatic effect on animals suffering from touch-evoked pain caused by nerve injuries or diabetes. Treating the skin with OB-1 completely eliminated this type of pain. This indicates that its cause might be an increase in STOML3's modulation of Piezo2, which means that dampening it would be a way of treating the condition.
"The results are encouraging for many reasons," Prof. Lewin says. "What this represents is a new strategy that arose from understanding the mechanisms that turn sensations of touch into pain. From what we can tell so far, the substance only affects a very specific type of mechanoreceptor that has both STOML3 proteins and Piezo2 channels. It dampens the perception of painful stimuli in a way that doesn't affect other signals that the animal needs. And the effects are reversible."
Prof. Lewin says that developing the substance into a treatment will be a long process. But at some point it should be ready for trials in people. If human patients respond the same way, this will represent a major step in treating a neuropathology that has a devastating effect on the lives of many people.
About Max Delbrück Center
The Max Delbrück Center for Molecular Medicine in the Helmholtz Association was founded in January 1992 with the goal of linking basic science to clinical research. The MDC was named for Max Delbrück, a physicist, biologist, and Nobel Prize winner. Currently the institute employs more than 1600 people from nearly 60 countries; over 1300 of those are directly involved in research. The MDC's annual budget is over 80 million Euros, along with substantial third-party funding obtained by individual scientific groups.
For more information, please visit http://www.mdc-berlin.de
About Charité – Universitätsmedizin Berlin
With a total of 3,001 beds, Charité – Universitätsmedizin Berlin is one of the largest university hospitals in Europe. Charité spans 4 campuses and comprises approximately 100 Departments and Institutes. In 2015, Charité treated more than 142,000 outpatient and more than 663,000 inpatient cases. With approximately 16,900 staff employed across the Charité group of companies, Charité is one of the largest employers in Berlin. In 2015, the Charité university hospital recorded a turnover of more than €1.6 billion. The areas of research, teaching, and health care delivery are intricately linked, resulting in a working relationship that is characterized by interdisciplinary cooperation. In 2015, Charité was able to secure more than €149 million in third-party funding, as well as approximately €202 million in state funding for research and teaching. With approximately 7,000 future physicians and dentists currently enrolled in degree courses, Charité is one of the largest medical faculties in Germany. http://www.charite.de/